vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $10.7M, roughly 1.7× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -0.8%, a 24.3% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs -25.7%). Over the past eight quarters, Arbutus Biopharma Corp's revenue compounded faster (-13.2% CAGR vs -15.9%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
ABUS vs CTMX — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $18.7M |
| Net Profit | $2.5M | $-154.0K |
| Gross Margin | — | — |
| Operating Margin | 13.9% | -6.9% |
| Net Margin | 23.5% | -0.8% |
| Revenue YoY | 522.2% | -25.7% |
| Net Profit YoY | 112.7% | 97.6% |
| EPS (diluted) | $0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $10.7M | $18.7M | ||
| Q1 25 | — | $50.9M | ||
| Q4 24 | — | $38.1M | ||
| Q3 24 | — | $33.4M | ||
| Q2 24 | — | $25.1M | ||
| Q1 24 | — | $41.5M | ||
| Q4 23 | $2.1M | $26.6M | ||
| Q3 23 | $4.7M | $26.4M |
| Q2 25 | $2.5M | $-154.0K | ||
| Q1 25 | — | $23.5M | ||
| Q4 24 | — | $18.9M | ||
| Q3 24 | — | $5.7M | ||
| Q2 24 | — | $-6.5M | ||
| Q1 24 | — | $13.8M | ||
| Q4 23 | — | $837.0K | ||
| Q3 23 | $-20.1M | $3.0M |
| Q2 25 | 13.9% | -6.9% | ||
| Q1 25 | — | 44.4% | ||
| Q4 24 | — | 46.4% | ||
| Q3 24 | — | 12.3% | ||
| Q2 24 | — | -33.7% | ||
| Q1 24 | — | 28.1% | ||
| Q4 23 | -967.2% | -2.3% | ||
| Q3 23 | -462.8% | 11.8% |
| Q2 25 | 23.5% | -0.8% | ||
| Q1 25 | — | 46.2% | ||
| Q4 24 | — | 49.6% | ||
| Q3 24 | — | 17.2% | ||
| Q2 24 | — | -26.0% | ||
| Q1 24 | — | 33.3% | ||
| Q4 23 | — | 3.1% | ||
| Q3 23 | -431.6% | 11.3% |
| Q2 25 | $0.01 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $-0.12 | — | ||
| Q3 23 | $-0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $49.0M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $119.9M |
| Total Assets | $103.3M | $175.1M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $37.4M | $49.0M | ||
| Q1 25 | — | $47.6M | ||
| Q4 24 | — | $38.1M | ||
| Q3 24 | — | $40.6M | ||
| Q2 24 | — | $43.2M | ||
| Q1 24 | — | $36.2M | ||
| Q4 23 | $126.0M | $17.2M | ||
| Q3 23 | $17.5M | $26.0M |
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $0 | — | ||
| Q3 23 | $0 | — |
| Q2 25 | $83.0M | $119.9M | ||
| Q1 25 | — | $25.0M | ||
| Q4 24 | — | $-456.0K | ||
| Q3 24 | — | $-23.5M | ||
| Q2 24 | — | $-31.2M | ||
| Q1 24 | — | $-31.7M | ||
| Q4 23 | $106.0M | $-47.4M | ||
| Q3 23 | $119.3M | $-51.2M |
| Q2 25 | $103.3M | $175.1M | ||
| Q1 25 | — | $98.5M | ||
| Q4 24 | — | $120.5M | ||
| Q3 24 | — | $139.0M | ||
| Q2 24 | — | $159.2M | ||
| Q1 24 | — | $184.7M | ||
| Q4 23 | $144.4M | $201.8M | ||
| Q3 23 | $158.6M | $221.2M |
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 0.00× | — | ||
| Q3 23 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-15.8M |
| Free Cash FlowOCF − Capex | — | $-15.8M |
| FCF MarginFCF / Revenue | — | -84.6% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $-15.7M | $-15.8M | ||
| Q1 25 | — | $-21.0M | ||
| Q4 24 | — | $-19.9M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | — | $-19.5M | ||
| Q1 24 | — | $-26.0M | ||
| Q4 23 | $-17.3M | $-22.0M | ||
| Q3 23 | $-21.8M | $-18.2M |
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-21.2M | ||
| Q4 24 | — | $-20.0M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | — | $-19.6M | ||
| Q1 24 | — | $-26.2M | ||
| Q4 23 | — | $-22.2M | ||
| Q3 23 | $-21.8M | $-18.3M |
| Q2 25 | — | -84.6% | ||
| Q1 25 | — | -41.6% | ||
| Q4 24 | — | -52.5% | ||
| Q3 24 | — | -62.1% | ||
| Q2 24 | — | -78.2% | ||
| Q1 24 | — | -63.1% | ||
| Q4 23 | — | -83.5% | ||
| Q3 23 | -468.4% | -69.2% |
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.3% | ||
| Q4 23 | 0.0% | 1.0% | ||
| Q3 23 | 0.7% | 0.0% |
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | — | -3.61× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -1.89× | ||
| Q4 23 | — | -26.24× | ||
| Q3 23 | — | -6.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
